| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Tumor Biology [L L N., B S., B Y., P L., M G., M M., J C., W R B., M L.], Biostatistics [G H.], and Virology [E F.], Schering-Plough Research Institute, Kenilworth, New Jersey 07033
SCH66336 is a p.o.-active, farnesyl protein transferase inhibitor. SCH66336 inhibits farnesylation of RAS and other proteins in tumor cells and suppresses tumor growth in human xenograft and transgenic mouse cancer models in vivo. SCH58500 is a replication-deficient, recombinant adenovirus, which expresses the human p53 tumor suppressor. In preclinical models, SCH58500 has therapeutic efficacy against a wide range of human tumor types containing nonfunctional p53 and enhanced activity in combination with many chemotherapeutic drugs. Here we report that combination therapy with SCH66336 and SCH58500 has synergistic or additive antiproliferative effects on a panel of tumor cells lines in vitro. The efficacy of the three-drug combination of SCH66336, SCH58500, and paclitaxel was also examined in vitro. Each two-drug interaction displayed such marked synergy, the addition of a third drug to the statistical model could only yield additivity. Greater combined efficacy for SCH66336 and SCH58500 was also observed in vivo in the DU-145 human prostate and wap-ras/F transgenic mouse cancer models.
This article has been cited by other articles:
|
|
 |
|
  A. G. Papatsoris, M. V. Karamouzis, and A. G. Papavassiliou The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics Mol. Cancer Ther., March 1, 2007; 6(3): 811 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Basso, A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling: ROLE IN FTI ENHANCEMENT OF TAXANE AND TAMOXIFEN ANTI-TUMOR ACTIVITY J. Biol. Chem., September 2, 2005; 280(35): 31101 - 31108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lee, H. Moon, K.-H. Chun, Y.-S. Chang, K. Hassan, L. Ji, R. Lotan, F. R. Khuri, and W. K. Hong Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells J Natl Cancer Inst, October 20, 2004; 96(20): 1536 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Khuri, B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors Clin. Cancer Res., May 1, 2004; 10(9): 2968 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Carroll, L. L. Nielsen, S. B. Pruett, and J. M. Mathis The Role of Natural Killer Cells in Adenovirus-mediated p53 Gene Therapy Mol. Cancer Ther., November 1, 2001; 1(1): 49 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson The Farnesyl Protein Transferase Inhibitor SCH66336 Is a Potent Inhibitor of MDR1 Product P-glycoprotein Cancer Res., October 1, 2001; 61(20): 7525 - 7529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Nielsen, M. Gurnani, B. Shi, G. Terracina, R. C. Johnson, J. Carroll, J. M. Mathis, and G. Hajian Derivation and Initial Characterization of a Mouse Mammary Tumor Cell Line Carrying the Polyomavirus Middle T Antigen: Utility in the Development of Novel Cancer Therapeutics Cancer Res., December 1, 2000; 60(24): 7066 - 7074. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
